MedTrace Logo

Effect of Adipose Tissue Derived Autologous Mesenchymal Stem Cell Concentrate on Bone Quality in Mandibular Fracture Healing.

NCT07671183 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-06-29

No results posted yet for this study

Summary

* The goal of study is to evaluate the effectiveness of adipose tissue derived-MSCs concentrate application in mandibular fractures. The main question it aims to answer is: Does intervention enhance bone quality, reduce complications and reduce bone regeneration time.
* Researchers will compare the effectiveness of adipose tissue derived-MSCs concentrate application with ORIF to ORIF alone to see if MSCs improve healing in mandibular fractures.
* Participants will:

* Be managed either by adipose tissue derived-MSCs concentrate application with ORIF or ORIF alone.
* Undergo CBCT immediately (T1) and 3 months (T4) postoperatively for bone density radiographic evaluation
* Visit the clinic postoperatively at one week (T2), one month (T3), three months (T4) for clinical examination

Conditions

  • Mandible Fracture

Interventions

PROCEDURE

Adipose tissue derived mesenchymal stem cells concentrate application in addition to the open reduction and internal fixation.

Abdominal fat liposuction will be carried out, microfragmentation of adipose tissue will be performed. Then the filtrate containing mesenchymal stem cells concentrate will be applied to the fracture line before and following fixation with titanium plates and screws .

PROCEDURE

Open reduction and internal fixation

Open reduction and internal fixation of fracture line with titanium plates and screws

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Mostafa Mohamed El-Gangehi, Professor · Faulty of Dentistry, Cairo University

  • Walaa Kadry, Associate Professor · Faulty of Dentistry, Cairo University

  • Sameh Mekhemer, Professor · Faulty of Dentistry, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-02-28
Completion
2027-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07671183 on ClinicalTrials.gov